Still hungry on your first day of Mounjaro — is that normal?

The 2.5mg starter dose prioritises tolerability, meaningful appetite changes usually emerge later in the titration schedule, not on day one.
Tirzepatide works on two gut-hormone pathways (GIP and GLP-1), slowing gastric emptying; this effect builds with consistent weekly dosing, not from a single injection.
Many people notice hunger shifting in quality before it shifts in quantity, meals may feel slightly heavier, or cravings quieter, before overall appetite drops noticeably.
Tracking your hunger on a simple 1–10 scale each morning takes under a minute and gives you useful data to share with your prescriber at review.

Feeling hungry on your first day of Mounjaro is completely normal. The 2.5mg starting dose is a tolerability step, not a therapeutic one — its job is to let your body adjust gradually, and appetite suppression typically follows over days to weeks rather than hours. You haven't missed anything; the medicine is working as designed. These are prescription-only medicines that require clinical assessment, and a prescriber will guide you through what to expect as your dose progresses.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Why hunger on day one doesn't tell you how Mounjaro will work for you

The starter dose isn't supposed to suppress appetite yet

This is the question our prescribers hear almost every week: I took my first pen yesterday and I'm still hungry, has something gone wrong? Nothing has. The 2.5mg dose exists for one purpose: to let your digestive system meet tirzepatide without being overwhelmed. Nausea, reflux and stomach discomfort are the most common early complaints on GLP-1 medicines, and starting low dramatically reduces how many people experience them at a level that disrupts daily life.

Appetite regulation through the GIP and GLP-1 receptors is dose-dependent. At 2.5mg, plasma concentrations are modest; the slowing of gastric emptying and the signals that reduce hunger between meals are present but subtle. Think of it less as a switch and more as a dimmer being turned from zero. By the time you reach your individually prescribed maintenance dose (which your prescriber will move you towards in gradual steps) those effects are considerably stronger. The experience of persistent hunger on Mounjaro at higher doses is a different conversation entirely.

The NHS's patient information for tirzepatide explains that the treatment schedule begins at 2.5mg and is titrated by a prescriber, see the NHS medicines page on tirzepatide for the full overview of what to expect during treatment.

What you might notice instead of a sudden drop in hunger

Even on day one, some people report subtler shifts that are easy to overlook: a meal feels heavier sooner, a mid-morning snack seems less urgent, or a craving for something specific fades before they act on it. These are real early signals. They're not the dramatic appetite suppression that clinical trial participants described at maintenance doses, but they're the first signs that the mechanism is active.

Food choices matter more now than they might have before. Because tirzepatide slows the rate at which food leaves the stomach, high-fat meals can intensify the GI side effects and make it harder to distinguish normal early hunger from discomfort. Prioritising protein, staying well hydrated, and keeping portion sizes moderate makes the adjustment period more comfortable. The practical detail on what to eat on Mounjaro walks through this in more depth.

A simple checking habit that takes under a minute: before each meal for the first week, score your hunger from 1 to 10 and jot it down, even on your phone's notes app. By day seven you'll have a baseline that's far more useful in a clinical conversation than a general impression. Patterns emerge quickly, and your prescriber can use them to judge whether your titration is tracking normally.

The decision you're actually facing right now

Most people still hungry on day one are facing one of three things. First: entirely normal early-treatment physiology, and no action is needed beyond continuing as prescribed. Second: normal hunger, but heightened anxiety because the result wasn't instant, in which case what to expect when you're still hungry on Mounjaro day one gives a clearer picture of why this is so common. Third, and least common: a genuine question about whether this treatment is right for them at this point in their health journey, which is a conversation worth having with a prescriber rather than deciding unilaterally.

Stopping the pen after one dose because hunger persists is rarely the right call, and if you find yourself still hungry going into the next morning, our guide on being still hungry on day 2 of Mounjaro explains what that typically means and why it remains completely normal. Tirzepatide's clinical evidence (including the SURMOUNT-1 trial published in the New England Journal of Medicine, which followed thousands of adults over 72 weeks) documents outcomes that build across months, not days. The first week is adjustment, not assessment.

If you're considering your options or haven't yet started treatment, the full overview of Mounjaro covers how the medicine works, who it suits, and what the titration journey looks like from start to finish. Cost is sometimes a factor in whether people continue; a straightforward breakdown is on the Mounjaro price page.

When to contact your prescriber or seek medical help

Hunger alone on day one is not a clinical concern. A few things are. Severe or persistent stomach pain (particularly pain that spreads toward the back, with or without vomiting) warrants urgent medical attention and should not be waited out; this is the pattern associated with pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update on GLP-1 medicines. Signs of dehydration from repeated vomiting or diarrhoea also need prompt attention.

For milder concerns (nausea that isn't settling, uncertainty about whether your reaction is typical, or questions about your next dose) our aftercare team is available seven days a week. You can also browse commonly asked questions from patients at similar stages of treatment. If you'd like to discuss your suitability for Mounjaro with a prescriber, check your eligibility and start your free consultation.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions